JOINT FILING AGREEMENTJoint Filing Agreement • July 9th, 2021 • venBio Global Strategic Fund III, L.P. • Biological products, (no disgnostic substances)
This Schedule 13D was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 99.2.
JOINT FILING AGREEMENTJoint Filing Agreement • February 19th, 2021 • venBio Global Strategic Fund III, L.P. • Pharmaceutical preparations
This Schedule 13D was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 99.2.
JOINT FILING AGREEMENTJoint Filing Agreement • September 26th, 2022 • venBio Global Strategic Fund III, L.P. • Pharmaceutical preparations
This Schedule 13D was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 99.2 of the Schedule 13D.
JOINT FILING AGREEMENTJoint Filing Agreement • September 26th, 2022 • venBio Global Strategic Fund III, L.P. • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of CinCor Pharma, Inc. dated as of September 26, 2022 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • August 1st, 2024 • venBio Global Strategic Fund III, L.P. • Biological products, (no disgnostic substances)
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Artiva Biotherapeutics, Inc. dated as of August 1, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • January 11th, 2022 • venBio Global Strategic Fund III, L.P. • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of CinCor Pharma, Inc. dated as of January 11, 2022 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • September 26th, 2022 • venBio Global Strategic Fund III, L.P. • Biological products, (no disgnostic substances)
This Schedule 13D was executed by David Pezeshki on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 99.2 of the Schedule 13D.
JOINT FILING AGREEMENTJoint Filing Agreement • February 9th, 2024 • venBio Global Strategic Fund III, L.P. • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of RayzeBio, Inc. dated as of February 9, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
